Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy GOSS?
Source: Globenewswire
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: The stock price of Gossamer plummeted by 80% after the trial results failed to show statistical significance, which not only undermines investor confidence but also threatens the company's listing status on Nasdaq due to minimum bid price requirements.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, which could have significant implications for the company's future legal liabilities.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to file claims, reflecting the market's heightened uncertainty regarding Gossamer's future prospects, potentially leading to further investor withdrawals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.344
Low
10.00
Averages
12.33
High
15.00
Current: 0.344
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026, for participation.
- False Statements Allegation: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering the company's public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests and providing support for potential legal actions.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for the period from June 16, 2025, to February 20, 2026, due to failure to disclose critical patient data, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy (NASDAQ:NUAI) is involved in a class action lawsuit for the period from November 6, 2024, to December 29, 2025, for overstating progress on its Texas data center project and engaging in fraudulent schemes, with a deadline for lead plaintiffs also set for June 1, 2026.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is facing a class action lawsuit for the period from April 22, 2025, to February 9, 2026, due to misleading statements regarding its projected book-to-bill ratio, with a lead plaintiff deadline of June 5, 2026.
- Legal Consultation Advice: Investors who have suffered losses in these companies are encouraged to contact The Law Offices of Frank R. Cruz to understand their legal rights and remain vigilant regarding the class actions to ensure necessary actions are taken before the deadlines.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Stock Price Collapse: Gossamer Bio's shares plummeted over 80% on February 23, 2026, falling from $2.13 to $0.42, primarily due to the failure of its Phase 3 PROSERA study to meet the primary endpoint, severely undermining investor confidence.
- Executive Accountability: CEO Faheem Hasnain is named as an individual defendant, with allegations that he concealed critical trial design risks in the company's SEC filings and public statements, potentially exposing investors to significant losses.
- Legal Framework: Under Section 20(a) of the Securities Exchange Act of 1934, Hasnain faces personal liability as a controlling person for failing to fulfill his responsibilities during the company's violations of Section 10(b) and Rule 10b-5, which could lead to legal repercussions.
- Investor Action: Investors must apply by June 1, 2026, to become lead plaintiffs to participate in potential recoveries, with no upfront costs required for participation, ensuring that investor rights are protected.
See More
Gossamer Bio Investors Class Action Reminder
- Lawsuit Deadline: Investors in Gossamer Bio must file a lead plaintiff motion by June 1, 2026, to participate in a class action lawsuit concerning securities purchased between June 16, 2025, and February 20, 2026, aimed at recovering losses from the stock price collapse.
- Stock Price Crash: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study failed to meet its primary endpoint, resulting in an 80.3% drop in stock price to $0.42 per share, significantly harming investors and highlighting critical failures in the company's clinical trial.
- False Statements Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose adverse facts about its business and prospects, particularly regarding the low-risk characteristics of patients at Latin American sites.
- Legal Implications: Investors who purchased Gossamer securities during the class period may face legal implications; they are advised to contact legal counsel for more information and to participate in the lawsuit to protect their rights.
See More
Notice of Class Action Lawsuit for Gossamer Bio Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, to pay attention to the critical date of June 1, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that defendants made overwhelmingly positive statements to investors while concealing material adverse facts regarding the study design of Gossamer's Phase 3 PROSERA study, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its extensive experience and success in the field, prompting investors to carefully select qualified legal counsel.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Pomerantz LLP has filed a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices, with investors needing to apply by June 1, 2026, to become Lead Plaintiff and protect their interests.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its PROSERA study for seralutinib failed to meet its primary endpoint, showing only a +13.3 meter improvement in six-minute walk distance, which did not meet the required 0.025 alpha threshold, leading to a significant loss of market confidence.
- Stock Price Plummet: Following the trial results, Gossamer's stock price fell by 80.13%, dropping $1.71 to close at $0.42, reflecting extreme pessimism among investors regarding the company's future prospects.
- Severe Legal Consequences: The lawsuit could result in substantial damages for Gossamer, as Pomerantz LLP, a prominent class action law firm, has historically secured multimillion-dollar settlements for victims, indicating the potential impact of this case.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026, for participation.
- False Statements Allegation: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering the company's public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests and providing support for potential legal actions.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for the period from June 16, 2025, to February 20, 2026, due to failure to disclose critical patient data, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy (NASDAQ:NUAI) is involved in a class action lawsuit for the period from November 6, 2024, to December 29, 2025, for overstating progress on its Texas data center project and engaging in fraudulent schemes, with a deadline for lead plaintiffs also set for June 1, 2026.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is facing a class action lawsuit for the period from April 22, 2025, to February 9, 2026, due to misleading statements regarding its projected book-to-bill ratio, with a lead plaintiff deadline of June 5, 2026.
- Legal Consultation Advice: Investors who have suffered losses in these companies are encouraged to contact The Law Offices of Frank R. Cruz to understand their legal rights and remain vigilant regarding the class actions to ensure necessary actions are taken before the deadlines.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Stock Price Collapse: Gossamer Bio's shares plummeted over 80% on February 23, 2026, falling from $2.13 to $0.42, primarily due to the failure of its Phase 3 PROSERA study to meet the primary endpoint, severely undermining investor confidence.
- Executive Accountability: CEO Faheem Hasnain is named as an individual defendant, with allegations that he concealed critical trial design risks in the company's SEC filings and public statements, potentially exposing investors to significant losses.
- Legal Framework: Under Section 20(a) of the Securities Exchange Act of 1934, Hasnain faces personal liability as a controlling person for failing to fulfill his responsibilities during the company's violations of Section 10(b) and Rule 10b-5, which could lead to legal repercussions.
- Investor Action: Investors must apply by June 1, 2026, to become lead plaintiffs to participate in potential recoveries, with no upfront costs required for participation, ensuring that investor rights are protected.
See More
Gossamer Bio Investors Class Action Reminder
- Lawsuit Deadline: Investors in Gossamer Bio must file a lead plaintiff motion by June 1, 2026, to participate in a class action lawsuit concerning securities purchased between June 16, 2025, and February 20, 2026, aimed at recovering losses from the stock price collapse.
- Stock Price Crash: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study failed to meet its primary endpoint, resulting in an 80.3% drop in stock price to $0.42 per share, significantly harming investors and highlighting critical failures in the company's clinical trial.
- False Statements Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose adverse facts about its business and prospects, particularly regarding the low-risk characteristics of patients at Latin American sites.
- Legal Implications: Investors who purchased Gossamer securities during the class period may face legal implications; they are advised to contact legal counsel for more information and to participate in the lawsuit to protect their rights.
See More
Notice of Class Action Lawsuit for Gossamer Bio Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, to pay attention to the critical date of June 1, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that defendants made overwhelmingly positive statements to investors while concealing material adverse facts regarding the study design of Gossamer's Phase 3 PROSERA study, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its extensive experience and success in the field, prompting investors to carefully select qualified legal counsel.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Pomerantz LLP has filed a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices, with investors needing to apply by June 1, 2026, to become Lead Plaintiff and protect their interests.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its PROSERA study for seralutinib failed to meet its primary endpoint, showing only a +13.3 meter improvement in six-minute walk distance, which did not meet the required 0.025 alpha threshold, leading to a significant loss of market confidence.
- Stock Price Plummet: Following the trial results, Gossamer's stock price fell by 80.13%, dropping $1.71 to close at $0.42, reflecting extreme pessimism among investors regarding the company's future prospects.
- Severe Legal Consequences: The lawsuit could result in substantial damages for Gossamer, as Pomerantz LLP, a prominent class action law firm, has historically secured multimillion-dollar settlements for victims, indicating the potential impact of this case.
See More
